Gaucher’s Disease 2018-2028 – Forecast In 30 Major Markets –

Epidemiology Series: Gaucher’s Disease Forecast In 30 Major Markets
report has been added to’s

This report provides the current prevalent population for GD across 30
Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland,
Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Greece,
Romania, Slovenia, Czech Republic, Lithuania, Estonia, Russia, Turkey,
Japan, China, South Korea, India, Brazil, Mexico, Argentina) split by
gender and 5-year age cohort.

Along with the current prevalence, the report provides an overview of
the genotypes and the prevalence of associated disorders of GD. The
report also contains a disease overview of the risk factors, disease
diagnosis and prognosis along with specific variations by geography and

Providing a value-added level of insight from our analysis team, several
of the main co-morbidities of GD have been quantified and presented
alongside the overall prevalence figures. These sub-populations within
the main disease are also included at a country level across the 10-year
forecast snapshot.

Main symptoms and co-morbidities for GD include:

  • Splenomegaly
  • Hepatomegaly
  • Haematological conditions
  • Musculoskeletal conditions
  • Gall stones

Reasons to buy

  • Able to quantify patient populations in global GD market to target the
    development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of GD
    and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study
    sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid
    conditions on GD prevalent population.
  • Examination of the prevalence of the different causative gene
    mutations for GD.
  • Identify sub-populations within GD which require treatment.
  • Gain an understanding of the specific markets that have the largest
    number of GD patients.

Key Topics Covered:

  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Gaucher’s Disease
  • Features of Gaucher’s Disease Patients
  • Comorbidities of Gaucher’s Disease Patients
  • Abbreviations used in the Report
  • Other Services & Solutions
  • Reports & Publications
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database
  • References
  • Appendix

For more information about this report visit

Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Endocrine
and Metabolic Disorders Drugs